Long-Term Open-Label Extension Study of Oral Levosimendan

A phase 3 trial registered on ClinicalTrials.gov. The registry status is enrolling by invitation. It plans to enroll 800 participants.

Also called NCT07436689

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 800 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07436689
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Enrolling by invitation (from the registry)

Technical summary

Registry record NCT07436689. Allocation not applicable; no masking; primary purpose treatment. Start 2026-03-13 (actual); primary completion 2029-03 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Long-Term Open-Label Extension Study of Oral Levosimendan
Condition
Pulmonary Hypertension Associated With HFpEF
Intervention (Drug)
TNX-103
Lead sponsor
Tenax Therapeutics, Inc. (class: industry)

Record details

Record id
cardio:ct-nct07436689
Content hash
f36d37cb5bd4290b0f540457c1d622f89ae70de47d7e51a6633a871e80677b5c